No results for ‘’
Hester Biosciences Ltd
₹1839.10
(2.37%)
Mon, 25 May 2026, 09:37 am
Health Technology
Pharmaceuticals: Major
24.5KHester Biosciences Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 8.13 | 6.69 | 8.74 | 7.95 | 11.32 | 7.99 | 9.49 | 9.65 | 7.99 | 31.96 | 22.13 | 27.57 | 53.25 | 31.62 | 26.98 | 47.36 | 58.75 | 48.58 | 62.57 | 38.81 |
| Price to book ratio | 2.75 | 1.38 | 1.84 | 1.03 | 1.67 | 1.26 | 1.21 | 1.57 | 1.01 | 4.83 | 4.18 | 5.32 | 9.70 | 7.41 | 3.91 | 7.14 | 8.88 | 4.62 | 4.05 | 3.39 |
| Price to sales ratio | 1.80 | 1.65 | 1.96 | 1.29 | 1.82 | 1.44 | 1.50 | 1.38 | 1.10 | 4.41 | 4.23 | 5.29 | 10.06 | 7.38 | 4.29 | 7.61 | 9.83 | 4.86 | 3.90 | 3.43 |
| Price to cash flow ratio | 20.50 | 2.86 | 6.15 | 4.79 | 4.98 | 7.43 | 6.30 | 10.60 | 23.61 | 20.85 | 27.87 | 20.69 | 40.05 | 31.50 | 26.69 | 29.49 | 353.52 | 112.34 | 33.64 | 20.43 |
| Enterprise value | 376.34M | 499.11M | 810.05M | 557.52M | 874.56M | 807.7M | 861.6M | 1.2B | 1.2B | 4.5B | 4.83B | 7.08B | 14.24B | 13.66B | 8.95B | 17.27B | 25.2B | 15.62B | 14.22B | 12.85B |
| Enterprise value to EBITDA ratio | 4.25 | 5.81 | 4.78 | 3.78 | 5.40 | 4.47 | 4.60 | 5.45 | 4.77 | 17.87 | 14.30 | 17.08 | 29.89 | 19.96 | 16.03 | 24.63 | 41.85 | 30.19 | 26.50 | 20.63 |
| Debt to equity ratio | 0.12 | 0.80 | 0.60 | 0.51 | 0.49 | 0.44 | 0.27 | 0.48 | 0.64 | 0.71 | 0.58 | 0.54 | 0.49 | 0.51 | 0.63 | 0.48 | 0.88 | 0.98 | 0.84 | 0.68 |
| Return on equity % | 0 | 24.77 | 22.93 | 13.51 | 15.57 | 17.02 | 14.12 | 14.57 | 13.29 | 15.84 | 20.85 | 21.06 | 19.69 | 26.14 | 15.41 | 16.04 | 16.11 | 9.87 | 6.61 | 9.07 |
Hester Biosciences Ltd Enterprise Value
The Hester Biosciences Ltd Enterprise Value is a key financial metric used by investors to evaluate Hester Biosciences Ltd's valuation, profitability, and overall financial performance. Tracking the Hester Biosciences Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Hester Biosciences Ltd (NSE: HESTERBIO, BSE: 524669) is currently trading at ₹1839.10, with a market capitalization of ₹15.28B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Hester Biosciences Ltd Enterprise Value is essential for fundamental analysis.
Hester Biosciences Ltd Enterprise Value Current Value
The current Hester Biosciences Ltd Enterprise Value stands at 12.85B.
The Hester Biosciences Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Hester Biosciences Ltd Enterprise Value Historical Trend
The Hester Biosciences Ltd Enterprise Value has shown the following historical trend:
- 2024: 12.85B
- 2023: 14.22B
- 2022: 15.62B
- 2021: 25.2B
- 2020: 17.27B
The decline in Hester Biosciences Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Hester Biosciences Ltd Enterprise Value Indicates for Investors
The Hester Biosciences Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Hester Biosciences Ltd.
Hester Biosciences Ltd Enterprise Value Analysis Summary
The Hester Biosciences Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Hester Biosciences Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Hester Biosciences Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.